Medigene AG (FRA:MDG1) is a biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. Medigene concentrates on the development of personalized T cell-based immunotherapies.
MediGene AG
FRA:MDG1 ISIN:DE000A161NA3
News
Medigene AG (FRA:MDG1), a clinical stage immune-oncology company focussing on the development of T cell-based immunotherapies for the treatment of cancer, announces that it has today sold 50% of its' stake in the private biotech company Immunocore Ltd., UK, for approximately 4.9 million GBP (approx. EUR 6.1 million).
MediGene AG (FRA:MDG) Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
MediGene AG (FRA:MDG) Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
MediGene AG (FRA:MDG) Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
MediGene AG (FRA:MDG) Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
MediGene AG (FRA:MDG) Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
MediGene AG (FRA:MDG) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
MediGene AG (OJ:MDG) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
MediGene AG (OJ:MDG) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
MediGene AG (OJ:MDG) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
13,516 COMPANY PROFILE VIEWS
- This Page Viewed: (Last 7 Days: 16) (Last 30 Days: 60) (Since Published: 8953)